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Abstract
The activation status of neutrophils can cycle from basal through primed to
fully activated (“green‐amber‐red”), and at least in vitro, primed cells can spon-
taneously revert to a near basal phenotype. This broad range of neutrophil
responsiveness confers extensive functional flexibility, allowing neutrophils to
respond rapidly and appropriately to varied and evolving threats throughout the
body. Primed and activated cells display dramatically enhanced bactericidal
capacity (including augmented respiratory burst activity, degranulation and long-
evity), but this enhancement also confers the capacity for significant unintended
tissue injury. Neutrophil priming and its consequences have been associated
with adverse outcomes in a range of disease states, hence understanding the
signalling processes that regulate the transition between basal and primed states
(and back again) may offer new opportunities for therapeutic intervention in
pathological settings. A wide array of host‐ and pathogen‐derived molecules is
able to modulate the functional status of these versatile cells. Reflecting this
extensive repertoire of potential mediators, priming can be established by a
range of signalling pathways (including mitogen‐activated protein kinases, phos-
phoinositide 3‐kinases, phospholipase D and calcium transients) and intracellular
processes (including endocytosis, vesicle trafficking and the engagement of
adhesion molecules). The signalling pathways engaged, and the exact cellular
phenotype that results, vary according to the priming agent(s) to which the
neutrophil is exposed and the precise environmental context. Herein we
describe the signals that establish priming (in particular for enhanced respira-
tory burst, degranulation and prolonged lifespan) and describe the recently
recognised process of de‐priming, correlating in vitro observations with in vivo
significance.
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1 | INTRODUCTION
Circulating neutrophils are quiescent, and in health the vast
majority undergo final disposal without encountering an acti-
vating signal. However, as first responders to infection or
injury, neutrophils need the functional versatility to enable
appropriate responses in the face of varied and evolving
threats (Figure 1). Unprimed neutrophils exposed to activating
agents such as fMLF, LTB4 or C5a secrete little or no granule
contents or reactive oxygen species (ROS). However, neu-
trophils that have been exposed to a range of agonists enter a
state of high alert, with the capacity to respond aggressively
(eg, through degranulation, respiratory burst activity and
increased lifespan) if a further activating stimulus is encoun-
tered. This pre‐activation or primed state was first recognised
in vitro,1 and shortly afterwards shown to occur in vivo in the
setting of systemic infection.2 A wide variety of priming
agents (chemokines, cytokines, alarmins, integrins, pathogen‐
derived molecules and mechanical forces) have been identi-
fied, and primed neutrophils circulate in vivo in many inflam-
matory diseases (eg, rheumatoid arthritis3 and cystic fibrosis4)
and pathological states (eg, trauma or cardiopulmonary
bypass5,6). In keeping with the requirement for dynamic regu-
lation of neutrophil activation (to ensure that maximal activa-
tion occurs only when and where required), primed cells also
have the flexibility to spontaneously “de‐prime” or revert back
to the unprimed quiescent state7; notably the retention of
primed cells in vascular beds may even facilitate this de‐esca-
lation (Ref8; Figure 1). Increased levels of circulating primed
neutrophils correlate with adverse outcomes,6,9 while defec-
tive neutrophil priming has been associated with recurrent
infections.10 This delicate balance between augmented micro-
bicidal function and increased risk of tissue injury is reflected
by the complex signalling processes that regulate neutrophil
priming. Herein we describe the signals that establish priming
and describe how neutrophils can de‐prime, correlating
in vitro observations with in vivo significance.
2 | DIVERSITY OF NEUTROPHIL
PRIMING IN VITRO AND IN VIVO
Primed neutrophils that are subsequently activated display
enhanced phagocytosis, ROS generation, degranulation,
release of bioactive mediators and NETosis.11 Numerous
primer/activator combinations induce these changes, but the
precise nature and duration of the primed phenotype varies;
for example priming induced by PAF is transient, while
growth factors such as GM‐CSF establish a more durable
primed state. Multiple molecular pathways including mito-
gen‐activated protein kinases (p38 and ERK1/2) and phos-
phoinositide 3‐kinases (PI3Ks) are required for priming to
occur; however, subtle differences between priming agents
are apparent even if convergence to common effector
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FIGURE 1 Neutrophil priming and de‐priming in vivo: potential sites and consequences. Circulating quiescent neutrophils (1) may
encounter intravascular priming agents (2) with the potential for local damage (3); if sequestered in the pulmonary capillary bed neutrophils have
the potential to gradually de‐prime and be released back in to the systemic circulation (4). Circulating neutrophils may become primed on
egressing the circulation both by engagement of adhesion receptors and by encountering endothelial‐bound or tissue‐associated priming agents
(5). Primed neutrophils ingest and kill bacteria, with the risk of collateral tissue damage (6). Primed neutrophils are also “primed to die” in
response to cues at the inflammatory site (7) or may de‐prime spontaneously (8)
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mechanisms occurs. For example, GM‐CSF and TNF both
promote p47phox phosphorylation to prime the respiratory
burst, but rely on ERK and p38 respectively12; RNAseq con-
firms that they activate both cytokine‐specific and shared
pathways.13 Identically primed neutrophils exposed to differ-
ent activating agents also initiate diverse signals; TNF‐
primed neutrophils treated with either the bacterial tri‐pep-
tide fMLF or with bacteria display enhanced ROS produc-
tion; both employ p38 signalling, but only fMLF also
entrains ERK.14 Other activating agents such as C5a and
LTB4 may also elicit different responses, but as most studies
have used fMLF our review focuses on this agonist.
Multiple priming influences co‐exist in disease states
in vivo. Different proportions of primed cells are seen to
circulate in individual patients,15 perhaps related to differ-
ences in priming signal intensity, neutrophil maturation or
the clearance of primed cells.16 Likewise, cells isolated
from pathological sites may display some, but not all of
the hallmarks of priming.17 Because of this in vivo com-
plexity, our understanding of priming and the signalling
processes that underlie it comes mostly from in vitro stud-
ies with isolated human neutrophils exposed to single pri-
mer/activator combinations (eg, TNF/fMLF; Figure 2).
However, neutrophil isolation itself may initiate partial
priming and isolated cells are not subject to the modifying
effects of other blood constituents on this process.18
Despite their limitations, in vitro approaches have provided
valuable insights, with the potential to progress to settings
recapitulating the complex in vivo environment, for exam-
ple co‐culture systems and animal models.
3 | SIGNALLING PRIMING
RESPONSES IN VIVO AND IN VITRO
3.1 | Reactive oxygen species production
Generation of phagosomal ROS by the multi‐component
NADPH oxidase is vital for pathogen killing, whereas the
secretion of extracellular ROS (which may be augmented
dramatically by priming, Figure 3) can cause major tissue
injury both in vitro and in vivo.19,20 Multiple molecular
pathways and cellular events must be activated for priming
of the respiratory burst to occur, with the timing and con-
tribution of each step being context dependent.
3.1.1 | Oxidase assembly at the cell
membrane
The production of ROS is mediated by the flavocy-
tochrome b558 (cytb558) oxidase, which is partly assem-
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FIGURE 2 Signalling events underlying TNF priming of fMLF‐mediated neutrophil activation. Priming with TNF activates multiple
signalling pathways, including p38 and ERK1/2, PI3K and NF‐κB, with both linear and overlapping downstream consequences. TNF‐mediated
phosphorylation of p47phox is largely dependent on p38, while both ERK1/2 and p38 mobilise secretory vesicles to the cell surface. Both of these
actions promote and enhanced the respiratory burst on subsequent exposure to an activating agent such as fMLF. Simultaneously, multiple
pathways influence the balance of pro‐ and anti‐apoptotic proteins such as Bad and Mcl1. On exposure to fMLF, enhanced PI3K activation acts
on the primed cell to enhance assembly and activation of the multi‐component NADPH oxidase. PI3K‐stimulated PLD activation, together with
calcium transients and changes in the cytoskeletal architecture, promote enhanced degranulation
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bled at membranes following specific phosphorylation
and cellular trafficking events upon priming. Components
of the cytb558 oxidase gp91phox and p22phox are predom-
inantly sited on granule membranes in resting cells, while
p47phox, p67phox, p40phox and Rac2 are cytosolic. Priming
mobilises cytb558‐containing granules and vesicles to the
plasma membrane14; in LPS priming this was shown to
increase expression of other relevant proteins such as
fMLF receptors (FPR1) and CD11b,21 although this may
not occur with all priming agents. The precise nature of
the trafficking processes and their signalling controls are
still debated and likely depend on the priming agent
used. For example, LPS priming requires cytoskeletal
changes and NADPH oxidase pre‐assembly at Rab‐5 pos-
itive endosomes22; subtly different findings were reported
for PAF, which causes p40phox and p67phox, but not
p47phox or gp91phox to re‐locate to Rab5‐positive endo-
somes (Ref23; Figure 3). However, the fundamental
importance of granule trafficking to the priming process
is shown by experiments blocking exocytosis either
directly or indirectly (by the inhibition of clathrin‐
mediated endocytosis), which prevents priming of the res-
piratory burst by either TNF or PAF.24,25 The importance
of the subtle differences between priming agents and the
precise in vivo dependence of priming on endocytosis/ex-
ocytosis remain to be elucidated.
3.1.2 | Phosphorylation of oxidase
components
In resting cells, p47phox is nonphosphorylated; on cellular
activation it becomes highly phosphorylated (Figure 3) and
undergoes conformational changes, facilitated by the pro-
line isomerase Pin1 (reviewed in ref26), unmasking multiple
binding domains for interaction with other oxidase compo-
nents and membrane phospholipids. Several priming agents
induce p47phox phosphorylation at residue S345 via the
JAK/STAT, p38 or ERK1/2 signalling cascades,12,27-28
with the precise pathway depending on the priming agent.
Subsequent exposure to activators leads to enhanced phos-
phorylation at further sites.11
The in vivo relevance of these events is demonstrated
by neutrophils from patients with myeloproliferative dis-
ease due to a gain‐of‐function JAK2 mutation (V617F);
such neutrophils exhibit constitutive S345 p47phox phos-
phorylation and are basally primed.29 A similar phenotype
has been observed in neutrophils from inflamed rheumatoid
joints, where a competitive inhibitory S345‐based peptide
abolishes ROS production by these inflammatory cells,
suggesting that this phosphorylation is critical for primed
NADPH oxidase activity in vivo.12
NF‐κB signalling also contributes to p47phox phosphory-
lation in LPS‐primed mouse neutrophils.30 Decreased
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FIGURE 3 Cellular and molecular events involved in neutrophil priming. Circulating or unstimulated neutrophils are largely spherical and
express a limited number of receptors on their surface; p47phox, a cytosolic component of the NADPH oxidase, is present in the cytosol in a
nonphosphorylated state. Priming induces neutrophil shape change with polarisation, and secretory vesicle exocytosis increases the expression of
NADPH oxidase subunits gp91phox and p22phox, as well as other molecules such as integrins and FPR1. p47phox becomes partially
phosphorylated, and following interaction with Pin1, undergoes a conformational change facilitating interactions with membrane phospholipids
and other oxidase components. NADPH oxidase components such as p67phox and p40phox are recruited to Rab5/EEA1 positive endosomes in
preparation for delivery to the plasma membrane. Subsequent activation of the primed neutrophil enables a fully functional NADPH oxidase
complex to become assembled and activated, associated with enhanced granule protein exocytosis
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neutrophil p47phox phosphorylation induced by LPS has
been reported patients carrying mutations in NF‐κB‐
modulating proteins.31 This resulted in reduced (NEMO‐
deficient cells) or absent (IRAK4‐deficiency) LPS priming
of the respiratory burst.31 Phosphorylation events involving
other oxidase components are important for NADPH oxi-
dase activation,26 but their relevance to priming is yet to be
established.
3.1.3 | Interactions with membrane
phospholipids
We have previously shown that PI3K‐dependent PtdIns
(3,4,5)P3 (PIP3) generation correlates with ROS release
in vitro, and TNF‐primed fMLF‐stimulated human neu-
trophils display biphasic PI3K activation, with the second
(PI3Kδ isoform‐dependent) phase governing primed ROS
generation.32 The mechanism(s) by which PI3K regulates
the primed respiratory burst appear context dependent, but
interactions with PI3K‐generated 3‐phosphorylated lipids
promote membrane translocation of oxidase components
(reviewed in ref33). Additionally, PI3K activates the Rac‐
GEF P‐Rex1 and hence Rac, a critical NADPH oxidase‐
activating small GTPase; mouse neutrophils lacking
P‐Rex1 exhibit a defect in LPS‐ROS formation.34 Interest-
ingly, P‐Rex1 has been identified as a potential anti‐inflam-
matory target in a mouse model of pulmonary fibrosis,35
although whether and how this relates to its impact on neu-
trophil priming is unclear.
3.2 | Priming of neutrophil degranulation
Neutrophil granules and secretory vesicles comprise a
reservoir of antimicrobial products, NADPH oxidase com-
ponents and receptors. Primary (azurophilic) granules incor-
porate histotoxic contents such as myeloperoxidase (MPO)
and neutrophil elastase (NE). Secondary (specific) granules
and tertiary (gelatinase) granules include adhesion mole-
cules such as CD11b and FPR1. Secretory vesicles contain
FPR1, CD11b and cytochrome b558. Priming alone leads to
exocytosis of secretory and gelatinase vesicles, with subse-
quent increased release of specific and azurophilic granule
contents on exposure to activating agents.36-37 Several sig-
nalling pathways regulating primed ROS production also
influence degranulation. Cadwallader and colleagues38
found that TNF‐induced PI3K‐dependent phospholipase D
(PLD) activation is required for enhanced MPO and ROS
secretion, and PLD activation likewise signals GM‐CSF
priming of NE release.39 Potera et al37 noted involvement
of p38 and ERK1/2 in TNF‐augmented granule release, but
ROS suppressed the magnitude of this response, suggesting
a negative feedback role. Consistent with this, our group
has shown that hypoxia sufficient to suppress NADPH
oxidase function enhances primed (GM‐CSF or PAF) neu-
trophil degranulation in a PI3Ky‐dependent fashion.40
Primed granule exocytosis is tightly regulated and hier-
archical; in an in vivo skin blister model, complete mobili-
sation of secretory vesicles was accompanied by discharge
of 38% of tertiary, 22% of secondary and just 7% of pri-
mary granule proteins.41 A similar rank order of degranula-
tion was observed in response to calcium ionophore, and
calcium chelation abolishes secretion of all but secretory
vesicles.42 Many priming agents induce calcium transients
and enhance activation‐induced calcium flux,39 influencing
dynamic changes in the actin cytoskeleton required for
granules mobilisation to the plasma membrane.43 Phospho‐
proteome analysis of primed neutrophils36 supports the
importance of cytoskeletal reorganisation in priming for
granule protein exocytosis. How these and other priming‐
relevant pathways might be manipulated in vivo is an
important question. Of note, enhanced NE release associ-
ated with priming and tissue injury has been detected in
several diseases,5,44 and inhibition of neutrophil exocytosis
was protective in rodent models of lung injury45-47 demon-
strating the in vivo relevance of this process and its poten-
tial value as a therapeutic target.
3.3 | Delayed apoptosis
Most priming agents also delay the ability of neutrophils to
undergo constitutive apoptosis, extending the time frame
over which these cells may combat infection or cause
bystander injury. We and others have shown the effect of
TNF to be biphasic, with an early increase in cell death
followed by extended survival; TNF and other pro‐survival
priming agents such as GM‐CSF induce changes in the
expression, stability and function of an array of both pro‐
and anti‐apoptotic proteins,48 with the balance between
these pathways determining neutrophil lifespan (Figure 2).
Thus, even when priming promotes survival, neutrophils
encountering subsequent stimuli at the inflammatory site
are also primed to die (eg, through enhanced expression of
Bim48).
Priming agents such as GM‐CSF delay apoptosis pre-
dominantly by increasing the stability of the anti‐apoptotic
protein Mcl‐1, which normally has a very fast intracellular
turnover time. Mcl‐1 levels are down‐regulated by protea-
somal degradation and caspase activation but preserved by
sustained activation of the PI3K effector Akt.49 Neutrophil
Mcl‐1 levels have been reported to be higher in neutrophils
isolated from patients with COPD50 and sepsis.51 In an ani-
mal model, attenuating Mcl‐1 down‐regulation inhibited
neutrophil apoptosis and delayed the resolution of
endotoxin‐mediated lung inflammation,52 highlighting the
potential for manipulating these pathways in vivo. PI3K‐
dependent signalling also plays a role in the pro‐survival
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effects of GM‐CSF and TNF, in part via Akt‐mediated
phosphorylation of the pro‐apoptotic Bcl‐2 family member
Bad.53 Neutrophils treated with PAF are dependent on both
ERK1/2 and PI3K survival signals, with ERK‐ and PI3K‐
dependent Bad phosphorylation on residues S112 and
S136, respectively.54
Understanding and elucidating these varied signalling
pathways in the context of disease is important, as modula-
tion of neutrophil activation status and apoptosis represents
an emerging therapeutic strategy in chronic “granulocyte‐
dominated” inflammatory disease.55
4 | THE INTERPLAY OF PRIMING
AND ADHESION
Most in vitro experiments are performed on neutrophils in
suspension culture, stimulated with soluble agonists; while
this may be relevant to circulating neutrophils exposed to
priming agents in the bloodstream (Figure 1), adherent or
postmigratory neutrophils display significantly altered func-
tional properties. Priming agents impact greatly on the bio-
physical and adhesive properties of neutrophils and
likewise the process of adhesion modifies neutrophil
responses in a manner very akin to priming.
Priming up‐regulates the surface expression of neutrophil
adhesion receptors such as CD11b (Figure 3) by mobilisa-
tion of secretory vesicles, both in vitro56 and in vivo57 and
further increases the affinity (or avidity) of such integrins via
“inside‐out” signalling. Engagement of integrins during
transmigration stimulates “outside‐in” signalling, which
together with exposure to endothelial‐bound mediators such
as PAF ensures that neutrophils are primed as they egress
(Ref58; Figure 1). The engagement of such receptors can
alter neutrophil responsiveness dramatically; for example
cells adherent to fibronectin release substantial ROS on
exposure to TNF (normally regarded as a priming agent
rather than an activating stimulus)59 and display sequential
PI3K and δ‐PKC activation, with δ‐PKC‐dependent phos-
phorylation of p47phox.60 Of note, these effects are agonist
specific, as treatment of adherent cells with fMLF resulted in
δ‐PKC‐independent ROS generation.61 Reminiscent of the
biphasic PI3K activation seen in neutrophils primed in sus-
pension,32 stimulation of adherent mouse neutrophils
induced a biphasic NADPH oxidase response, the initial
phase being signalled by PI3Kγ, with a role for PI3Kα/δ in
the subsequent prolonged phase; src‐family kinases were
critical for both phases in this setting.61
Neutrophil L‐selectin (CD62L) mediates initial rolling
interactions with the endothelium, and its rapid, often near‐
total shedding provides a sensitive marker of neutrophil
priming both in vitro56 and in vitro.57 Circulating neu-
trophils in mice expressing an L‐selectin point mutation
(N138G), which modifies force‐catch bonds induced by
mechano‐stimulation, form unstable aggregates and are
primed in vivo62; this priming status is associated with
enhanced bacterial clearance, but increases inflammatory
injury and enlarged venous thrombi, again emphasising the
precarious tightrope between host defence and tissue injury.
These primed neutrophils do not adhere via β2‐integrin dif-
ferently from control neutrophils, suggesting an alternative
form of priming by mechanotransduction.63
5 | DE‐PRIMING
It was initially assumed that neutrophil priming was an
irreversible process. However, proof of concept experi-
ments with PAF demonstrated the potential for near‐com-
plete recovery back to a quiescent or de‐primed state. With
PAF this was shown to be a spontaneous event, with a re‐
setting of fMLF‐triggered NADPH oxidase response and
near‐complete recovery from a polarised to a rounded mor-
phology.7 Our group has recently shown the potential for
this process to occur in vivo in humans, with immediate
(first pass) trapping of injected exogenously (GM‐CSF)‐
primed neutrophils within the very narrow pulmonary cap-
illaries, followed by their subsequent gradual release back
into the systemic circulation, a finding that we propose to
reflect in situ de‐priming.8 Furthermore, the ability of
repeated mechanical deformation of neutrophils (achieved
by optical lasers or by passage through a series of multiple
5‐μm micro‐channels) highlights the mechano‐sensitive nat-
ure of neutrophils and the potential for active and rapid de‐
priming of these cells.63 This recovery option for primed
neutrophils fits with mathematical modelling of the number
of circulating primed neutrophils found in disease settings64
and may play a role in the now well‐recognised capacity of
murine neutrophils to return from sites of inflammation
back to the systemic circulation (retro‐transmigration)65 or
to the bone marrow and lymph node.66 Mechanistically,
however, very little is known about the effects of de‐prim-
ing on cell signalling events or the restoration of neutrophil
cell surface receptors and molecules involved in adhesion
and other immune functions. Likewise, whether the de‐
primed neutrophil is entirely indistinguishable from the
unprimed neutrophil and the true physiological role and
fate of these cells also needs to be determined.
In summary, priming appears to be one of the key pro-
cesses designed to regulate neutrophil function, with the
capacity to either restrain (unprimed/basal state) or greatly
enhance (primed state) their repertoire of functional
responses: this process therefore acts as a “volume switch”
for the functional reactivity of these cells to any activating
agonist they subsequently encounter. As part of the priming
process, this causes a dramatic change in cell contour and
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deformability, and re‐programmes the susceptibility of
these cells to undergo apoptotic cell death. Understanding
the signalling processes involved in priming and de‐prim-
ing should allow therapeutic opportunity to limit granulo-
cyte‐mediated tissue damage.
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